Status:
RECRUITING
Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Myelodysplastic Syndromes (MDS)
Leukemia Acute Myeloid - AML
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Until now, the development of personalized medicine in oncology has relied on the use of somatic biomarkers to help therapists choose the right molecule(s) to administer, based on the genetic and mole...
Eligibility Criteria
Inclusion
- Patients over 18 years of age
- Patients with acute myeloid leukemia
- Patient with myelodysplastic syndrome
- Person who has given non-opposition
- Patient who has signed an authorization to perform a constitutional genetic analysis (in the context of care)
- Need for effective contraception in patients of childbearing age
Exclusion
- Failure to obtain non-opposition
- Adults under guardianship or safeguard of justice
- Persons deprived of their liberty
- Patient participating in another research project
- Pregnancy in progress
Key Trial Info
Start Date :
June 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 14 2028
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06886425
Start Date
June 14 2021
End Date
June 14 2028
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de la Conception
Marseille, France, 13005